Invex Therapeutics Ltd (IXC.AX)
AUD 0.07
(0.0%)
AUD 0.07
(0.0%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 | -94.98 Thousand AUD | 100.0% |
| 2023 | -333.56 Thousand AUD | -128.92% |
| 2022 | -145.71 Thousand AUD | -587.36% |
| 2021 | -21.19 Thousand AUD | 81.86% |
| 2020 | -116.88 Thousand AUD | -36.51% |
| 2019 | -85.62 Thousand AUD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 FY | - AUD | 100.0% |
| 2024 Q2 | -128.59 Thousand AUD | 0.0% |
| 2024 Q4 | -94.98 Thousand AUD | 0.0% |
| 2023 Q1 | - AUD | 100.0% |
| 2023 Q4 | -333.56 Thousand AUD | 0.0% |
| 2023 Q2 | -472.7 Thousand AUD | 0.0% |
| 2023 Q3 | - AUD | 100.0% |
| 2023 FY | -333.56 Thousand AUD | -128.92% |
| 2022 FY | -145.71 Thousand AUD | -587.36% |
| 2022 Q4 | -145.71 Thousand AUD | 0.0% |
| 2022 Q3 | - AUD | 100.0% |
| 2022 Q2 | -144.93 Thousand AUD | 0.0% |
| 2022 Q1 | - AUD | 100.0% |
| 2021 Q1 | - AUD | 100.0% |
| 2021 FY | -21.19 Thousand AUD | 81.86% |
| 2021 Q4 | -21.19 Thousand AUD | 0.0% |
| 2021 Q3 | - AUD | 100.0% |
| 2021 Q2 | -72.76 Thousand AUD | 0.0% |
| 2020 Q3 | - AUD | 100.0% |
| 2020 Q2 | -34.41 Thousand AUD | 0.0% |
| 2020 Q1 | - AUD | 0.0% |
| 2020 FY | -116.88 Thousand AUD | -36.51% |
| 2020 Q4 | -116.88 Thousand AUD | 0.0% |
| 2019 FY | -85.62 Thousand AUD | 0.0% |
| 2019 Q3 | - AUD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| AdAlta Limited | -1.67 Million AUD | 94.345% |
| Biome Australia Limited | 1.88 Million AUD | 105.029% |
| Radiopharm Theranostics Limited | -987.41 Thousand AUD | 90.381% |
| Biotron Limited | - AUD | Infinity% |
| Acrux Limited | 147 Thousand AUD | 164.614% |
| Alterity Therapeutics Limited | 1.00 AUD | 9498400.0% |
| Botanix Pharmaceuticals Limited | 1.2 Million AUD | 107.854% |
| BTC Health Limited | - AUD | Infinity% |
| Chimeric Therapeutics Limited | - AUD | Infinity% |
| CSL Limited | 8.93 Billion AUD | 100.001% |
| Clarity Pharmaceuticals Ltd | - AUD | Infinity% |
| Clinuvel Pharmaceuticals Limited | 10.62 Million AUD | 100.894% |
| Immutep Limited | 2.00 AUD | 4749250.0% |
| Memphasys Limited | 164.76 Thousand AUD | 157.649% |
| Neuren Pharmaceuticals Limited | - AUD | Infinity% |
| Noxopharm Limited | -2.35 Million AUD | 95.974% |
| Prescient Therapeutics Limited | - AUD | Infinity% |
| Race Oncology Limited | 16.4 Thousand AUD | 679.129% |
| Starpharma Holdings Limited | 2.4 Million AUD | 103.944% |
| Tissue Repair Ltd | 214.72 Thousand AUD | 144.235% |
| EZZ Life Science Holdings Limited | 1.4 Million AUD | 106.779% |
| Anatara Lifesciences Ltd | -671.09 Thousand AUD | 85.847% |
| Bio-Gene Technology Limited | - AUD | Infinity% |
| Zelira Therapeutics Limited | 1.25 Million AUD | 107.585% |
| Patrys Limited | - AUD | Infinity% |
| Orthocell Limited | 1.17 Million AUD | 108.072% |
| Imugene Limited | - AUD | Infinity% |
| PYC Therapeutics Limited | -17.99 Million AUD | 99.472% |
| Proteomics International Laboratories Limited | - AUD | Infinity% |
| Cynata Therapeutics Limited | 108.2 Thousand AUD | 187.781% |
| Arovella Therapeutics Limited | - AUD | Infinity% |
| Nanollose Limited | - AUD | Infinity% |
| NeuroScientific Biopharmaceuticals Limited | - AUD | Infinity% |
| Amplia Therapeutics Limited | - AUD | Infinity% |
| Island Pharmaceuticals Limited | -877.24 Thousand AUD | 89.173% |
| Nyrada Inc. | - AUD | Infinity% |
| Telix Pharmaceuticals Limited | 17.31 Million AUD | 100.549% |
| Dimerix Limited | - AUD | Infinity% |
| PharmAust Limited | - AUD | Infinity% |
| Hexima Limited | - AUD | Infinity% |
| AnteoTech Limited | 221.85 Thousand AUD | 142.813% |
| Paradigm Biopharmaceuticals Limited | - AUD | Infinity% |
| Recce Pharmaceuticals Ltd | - AUD | Infinity% |
| Avecho Biotechnology Limited | 97.11 Thousand AUD | 197.803% |
| Actinogen Medical Limited | 108.82 Thousand AUD | 187.277% |
| Immuron Limited | 1.58 Million AUD | 105.994% |
| Argenica Therapeutics Limited | - AUD | Infinity% |